MILLENDO THERAPEUTICS Revenue and Competitors

Claim your profile

Detroit, MI USA

Location

$116.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • MILLENDO THERAPEUTICS's estimated annual revenue is currently $775k per year.(i)
  • MILLENDO THERAPEUTICS's estimated revenue per employee is $77,500
  • MILLENDO THERAPEUTICS's total funding is $116.5M.

Employee Data

  • MILLENDO THERAPEUTICS has 10 Employees.(i)
  • MILLENDO THERAPEUTICS grew their employee count by -76% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.2M28-56%$31.2MN/A
#2
$2.8M447%N/AN/A
#3
$2.2M34580%N/AN/A
#4
$4M62265%N/AN/A
#5
$4.5M29N/AN/AN/A
#6
$4.4M5712%$66.7MN/A
#7
$0.5M7-22%N/AN/A
#8
$48.2M3115%N/AN/A
#9
$1.4M18-33%$12.8MN/A
#10
$94.2M608-4%N/AN/A

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing's Syndrome (CS).

keywords:Licensing,Biotechnology,Healthcare,Pharmaceuticals

$116.5M

Total Funding

10

Number of Employees

$775k

Revenue (est)

-76%

Employee Growth %

N/A

Valuation

N/A

Accelerator

MILLENDO THERAPEUTICS News

2022-04-17 - Prader-Willi Syndrome Market to Exhibit Healthy Growth Rate ...

Millendo Therapeutics. Levo Therapeutics. Harmony Biosciences. Soleno Therapeutics. And many more. Prader-Willi Syndrome Therapies covered in...

2019-09-12 - Financial Review: Zynerba Pharmaceuticals (NASDAQ:ZYNE) vs. Millendo Therapeutics (NASDAQ:MLND)

Zynerba Pharmaceuticals (NASDAQ:ZYNE) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is ...

2019-08-31 - Millendo Therapeutics to Participate in September Investor Conferences

ANN ARBOR, Mich.--(BUSINESS WIRE)--. Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company developing novel ...

2019-08-17 - Millendo Therapeutics Appoints Tamara Joseph as General Counsel and Ryan Zeidan as Chief Development Officer

Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan ...

2019-03-27 - Roundup: QL Demo Day, Millendo Therapeutics, Strata Oncology, More

Share Share on Facebook Share on Twitter LinkedIn Email Reprints —Millendo Therapeutics, an Ann Arbor-based biopharmaceutical company developing treatments for rare diseases, has initiated a Phase 2b/3 clinical study investigating livoletide (AZP-531) in patients with Prader-Willi syndrome. Th ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.5M10-23%N/A
#2
$1.5M10150%N/A
#3
$1M10100%N/A
#4
$0.9M10N/AN/A
#5
N/A10N/AN/A